跳至主要内容
临床试验/CTRI/2026/02/104229
CTRI/2026/02/104229尚未招募2/3 期

An Open Randomized Control Clinical Trial TO Evaluate The Efficacy Of Aragvadhadi Kwath Yonidhavan In Kaphaj Yonivyapad With Special Reference To Vulvovaginal Candidiasis

Dr Rahila Nawsheen Afsar Khan1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2026年4月1日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
64
试验地点
1

研究概览

简要总结

In Ayurveda, a dedicated section on women’s health uses the term Yoni vyapad to encompass most gynecological disorder. 20 Yonirogas (Vinshati Yonivyapad) described in Ayurveda samhita by different Acharyas. Kaphaj Yonivyapad is one among them having Yonigata Shwetstrav, Yoni kandu and alpa yonivedana as Pradhan lakshan.

Vulvovaginal candidiasis (VVC), one of the most widespread fungal infections among women of reproductive age, is most often caused by Candida albicans. In India, an estimated 30% of women have vaginal candidiasis. It is characterized by symptoms like vaginal itching, white curd-like discharge, erythema and discomfort, significantly impacting the quality of life. Most antifungal regimen treatments are available for vaginal candidiasis can but have chance of side effects as well as recurrences.

The drug Aragvadha, Nimb & karanj having properties Kaphashamak, Kandughana, Krimighana, Stambhak Vranaropak, Antiseptic. Because of these properties it helps to overcome the symptoms of Kaphaj Yonivyapad by increasing local immunity and prevent recurrence of symptoms in patients.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
20.00 Year(s) 至 50.00 Year(s)(—)
性别
Female

入选标准

  • Married Patients having Kaphaj Yonivyapad i.e having following signs and symptoms
  • Yonigata shweta picchil strav, Yoni kandu Yonigat alpavedana
  • Patient selection of vaginal candidiasis will be confirmed after doing KOH Test.

排除标准

  • Unmarried female patients.
  • Known cases of sexually transmitted diseases.
  • Uncontrolled DM & HTN.
  • Pregnant women.
  • Cervical polyp and cervical erosion.
  • Patients with intolerable severe pain (VAS scale of 8 to 10) will be excluded.

研究者

发起方
Dr Rahila Nawsheen Afsar Khan
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Rahila Nawsheen Afsar Khan

Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate and Research Centre Ashta

研究点 (1)

Loading locations...

相似试验